|
PDT responder |
PDT non-responder |
p-value |
|
Age |
73.1 ± 6.9 |
71.7 ± 7.9 |
0.41 |
† |
Male/Female |
55/12 |
20/6 |
0.57 |
* |
GLD (mm) |
3639 ± 1602 |
3959 ± 1624 |
0.39 |
† |
Baseline BCVA logMAR |
0.69 ± 0.33 |
0.60 ± 0.36 |
0.25 |
† |
12M BCVA logMAR |
0.51 ± 0.41 |
0.72 ± 0.39 |
0.028 |
† |
BCVA change from
baseline logMAR |
-0.18 ± 0.37 |
0.12 ± 0.39 |
0.00098 |
† |
No. of PDT performed
(No. of eyes) |
1 (46)
2 (22)§ |
1 ( 8) #
2 (12)##
3 ( 5)
4 ( 1) |
|
|
PDT frequency/year |
1.3 ± 0.5 |
2.0 ± 0.8 |
0.000012 |
† |
p-values are calculated by *Χ-square test or † two-tailed t-test
GLD; greatest linear dimension, BCVA; best-corrected visual acuity, logMAR; logarithm of minimum angle resolution, PDT; photodynamic therapy
§Six cases underwent additional PDT due to the development of recurrence or new lesion 5.5±2.0 months (mean±SD) after the complete regression with a single PDT
#the cases ceased for the second PDT due to the increase of euxdative changes after the first PDT
##the cases who declined further treatment due to no effect |
